Given that enhanced production of IFN-I and IL-33 by pDCs promotes chronic inflammation and fibrosis, which are characteristic features of AIP and IgG4-RD, neutralization of IFN-I and IL-33 could be a new therapeutic option for these disorders. The gene discussed is IL33; the disease is autoimmune pancreatitis.